Timely Blockade of ICAM-1.LFA-1 Interaction Prevents Disease Onset in a Mouse Model of Emphysema

Abstract

Costimulatory blockade therapy can affect the progress of emphysema.

Inflammation and endothelial activation in early adulthood are associated with future emphysema: the CARDIA Lung Study

“…In the MESA (Multi-Ethnic Study of Atherosclerosis) Lung Study, ICAM-1, but not P-selectin, was associated with the progression of percentage emphysema measured serially over a 10-year time period [5]. In murine models, blockade of ICAM-1 prevents the development of experimental emphysema, strengthening the plausibility of its potential causal role in emphysema development [10]. The major strengths of our study are the recruitment and inclusion of healthy young adults, and the long duration of follow-up.…”